ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
Form:
lyophilized powder
Assay:
≥97% (SDS-PAGE)
Biological source:
human
Recombinant:
expressed in Sf21 cells
Mol wt:
protein 70 kDa
biological source
human
recombinant
expressed in Sf21 cells
assay
≥97% (SDS-PAGE)
form
lyophilized powder
mol wt
protein 70 kDa
technique(s)
cell culture | mammalian: suitable
impurities
endotoxin, tested
suitability
suitable for molecular biology
UniProt accession no.
storage temp.
−20°C
Quality Level
Gene Information
human ... TGFB1(7040)
General description
Research Area: Cell Signaling
TGF-β is released from degranulating platelets and secreted from nearly all cells in a biologically inactive complex which is unable to bind to cellular receptors and is not recognized by antibodies to TGF-β. The peptide can be activated by acidification, alkalinization, or action of chaotropic agents in vitro. The complex consists of TGF-β associated non-covalently with a protein designated as the latency associated peptide (LAP). TGF-β and LAP represent components of a pro-peptide that is cleaved in a post-golgi compartment prior to secretion. The recombinant human LAP is produced from a DNA sequence corresponding to the 278 amino acid residues of pre-pro-TGF-β1 terminating prior to the mature TGF-β1. LAP contains a Cys33 to Ser33 substitution. LAP contains 249 amino acids, generated after cleavage of a 29 amino acid residue signal peptide. LAP is a glycoslyated, disulfide linked homodimer.
TGF-β is released from degranulating platelets and secreted from nearly all cells in a biologically inactive complex which is unable to bind to cellular receptors and is not recognized by antibodies to TGF-β. The peptide can be activated by acidification, alkalinization, or action of chaotropic agents in vitro. The complex consists of TGF-β associated non-covalently with a protein designated as the latency associated peptide (LAP). TGF-β and LAP represent components of a pro-peptide that is cleaved in a post-golgi compartment prior to secretion. The recombinant human LAP is produced from a DNA sequence corresponding to the 278 amino acid residues of pre-pro-TGF-β1 terminating prior to the mature TGF-β1. LAP contains a Cys33 to Ser33 substitution. LAP contains 249 amino acids, generated after cleavage of a 29 amino acid residue signal peptide. LAP is a glycoslyated, disulfide linked homodimer.
Application
Latency Associated Peptide (LAP) may be used to inhibit transforming growth factor-β 1 activity in various biological systems.
Transforming Growth Factor-β1 Latency Associated Peptide human has been used to coat the cell culture inserts for cell migration assays to determine the functional effects of impeding αvβ6 endocytosis in vitro. It has also been used to coat non-tissue culture-treated 96-well plates for adhesion assays.
Biochem/physiol Actions
TGF-β1は多種の細胞から産生されますが、哺乳動物の血小板における濃度が最も高いと報告されています。
TGF-β1は多種の細胞から産生されますが、哺乳動物の血小板における濃度が最も高いと報告されています。哺乳動物の血小板には、TGF-β2の約4倍のTGF-β1が存在します。
Latency Associated Peptide (LAP) binds transforming growth factor-beta 1 (TGF-β1) to form a latent complex. The activity of TGF-β1 is primarily regulated through the activation of the latent molecule. LAP has the ability to stimulate epithelial cell migration, representing a new function for LAP in controlling monocyte trafficking and immune modulation. Following post-translational modification, TGF-β1 binds non-covalently to the LAP to establish latency. Due to its crucial function in modulating TGF-β1 activity, LAP plays a fundamental role in governing a range of TGF-β1 effects. LAP is expressed on immature dendritic cells and contributes to T cell differentiation. LAP exhibits both chemotactic and anti-inflammatory activity independently of active TGF-β1.
Physical form
凍結乾燥品(PBS溶液, 1.25mg BSA含有, 0.2μmフィルタ-濾過済み)。
Analysis Note
生物活性は、マウスHT-2細胞のTGF-β1阻害能により測定しています。
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
L3408-VAR: + L3408-BULK: + L3408-.025MG: + L3408-25UG-PW: + L3408-25UG:
jan
Latency associated peptide has in vitro and in vivo immune effects independent of TGF-beta1
Ali NA, et al,
PLoS ONE, 3(4), e1914-e1914 (2008)
Loss of MMP-8 in ductal carcinoma in situ (DCIS)-associated myoepithelial cells contributes to tumour promotion through altered adhesive and proteolytic function
Sarper M, et al.
Breast Cancer Research, 1-19 (2017)
Muge Sarper et al.
Breast cancer research : BCR, 19(1), 33-33 (2017-03-24)
Normal myoepithelial cells (MECs) play an important tumour-suppressor role in the breast but display an altered phenotype in ductal carcinoma in situ (DCIS), gaining tumour-promoter functions. Matrix metalloproteinase-8 (MMP-8) is expressed by normal MECs but is lost in DCIS. This
関連コンテンツ
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)